Open access · US-GOV
via ClinicalTrials.gov Clinical trial
LIver FRAilty Management IN Cirrhosis (LIFRAMIN)
Authors not listed
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 2024
Abstract
The goal of this clinical trial is to compare food for special medical purposes (Aminolife Plus, by Piemme Pharmatech) vs. placebo in improving muscle mass and function in a cohort of cirrhotic patients.
The main questions it aims to answer are:
* whether functional ability improves in cirrhotic-sarcopenic patients two months after taking the supplement compared with those not taking the supplement.
* whether weight, body mass index (BMI), lean mass, muscle mass, metabolically active mass, and phase angle as per bioimpedance analysis (BIA) in cirrhotic-sarcopenic patients increase two months after taking the supplement compared with those not taking the supplement.
* to assess quality-of-life indices in the two groups.
* to assess differences in groups in terms of plasma metabolite production in the two groups
This is a spontaneous, no PROFIT, pilot interventional study in the form of a randomized clinical trial (RCT), double-blind.
All patients will undergo simple sarcopenia risk identification questions (SARC-F test). All patients recognized to be at risk will be randomized to receive.
1. nutritional counseling according to guidelines + Aminolife plus 20 g/day (4 scoops) vs.
2. nutritional counseling according to guidelines + placebo 20 g/day (4 scoops) for a total of 60 days (2 months).
The manufacturing company will provide the product and placebo free of charge. Patients will undergo, at the first visit and at the follow-up visit anthropometric measurements and body composition assessment (by bioimpedance analysis).
In addition, 1 blood sample for metabolomic analysis will be taken at the same visits.
The study will last 12 months.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Anonymous. (2024). LIver FRAilty Management IN Cirrhosis (LIFRAMIN). <em>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</em>. https://clinicaltrials.gov/study/NCT06573229
Vancouver
Anonymous. LIver FRAilty Management IN Cirrhosis (LIFRAMIN). Fondazione Policlinico Universitario Agostino Gemelli IRCCS. 2024.
BibTeX
@misc{anon2024LIverF,
title = {LIver FRAilty Management IN Cirrhosis (LIFRAMIN)},
author = {Anonymous},
journal = {Fondazione Policlinico Universitario Agostino Gemelli IRCCS},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Fundacion Miguel Servet 2025
Open access · US-GOV
Effectiveness of Combined Therapeutic Exercise and Anti-Inflammatory Nutritional Supplementation in Frail, Malnourished Older Adults
Hospital Clinic of Barcelona 2021
Open access · US-GOV
Comparison of Two Nutritional Screening Tools for the Detection of Malnutrition in Patients with Liver Cirrhosis
Agricultural University of Athens 2022
Open access · US-GOV
Evaluation of a High Protein Plant Dominant Diet (HiProPlaDo) in Sarcopenia, Quality of Life and Metabolic Parameters in Patients With Liver Cirrhosis: A Randomized Clinical Trial
Centenario Hospital Miguel Hidalgo 2026
Open access · US-GOV
Effect of Egg Albumin and Agave Fructan Supplementation Combined With Functional Exercise on Muscle Mass, Physical Function, and Inflammatory Status in Patients Receiving Hemodialysis: A Randomized Controlled Trial
University of Saskatchewan 2015
Open access · US-GOV
The Benefits of Hemp Protein Supplementation During Resistance Training
China Medical University Hospital 2025
Open access · US-GOV